|Bid||20.71 x 1100|
|Ask||20.72 x 800|
|Day's range||19.57 - 20.76|
|52-week range||19.57 - 34.78|
|Beta (5Y monthly)||1.26|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||55.60|
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
There wouldn't be many who think Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 9.9x is...